Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Jack Reich has been appointed head of regulatory at Adial Pharmaceuticals. Formerly, Reich was CEO of Renova Therapeutics.
Steven Glazer has been named chief medical officer of Allero Therapeutics. Glazer was most recently the chief medical officer of Monta Bioscience. Allero has also hired Christophe Saillez as vice president of regulatory affairs. Saillez was previously the global regulatory lead at ActoBio Therapeutics.
Aptinyx has named its chief operating officer, Andy Kidd, president of the company. Before joining Aptinyx, Kidd was most recently senior vice president of strategy and business development at Baxter International.
ATAI Life Sciences
Rolando Gutierrez-Esteinou has been named chief medical officer of ATAI Life Sciences. In his most recent role at Aptinyx, Gutierrez-Esteinou served as senior vice president.
Jim Mazzo has been appointed president and CEO of Avellino. Mazzo most recently served as vice chairman and trustee for Chapman University.
Cardurion Pharmaceuticals has hired Howard Surks to assume the roles of chief scientific officer and head of translational medicine. Surks was most recently the head of translational medicine and clinical pharmacology U.S. at Sanofi.
Sheldon Koenig has been appointed chief operating officer of ESPERION. Most recently, Koenig was the executive vice president and chief commercial officer of Portola Pharmaceuticals.
Jerry Durso has been promoted from chief operating officer at Intercept Pharmaceuticals to CEO of the company. Prior to Intercept, Durso served as senior vice president and chief commercial officer at Sanofi.
Steve Blazejewski has taken the helm of Katena Products as the company’s newest CEO. Previously, Blazejewski was president of medical solutions at Cardinal Health.
Kymera Therapeutics has named William Leong vice president of chemistry, manufacturing and controls. Previously, Leong was senior vice president of technical operations at Complexa. Paul Cox was appointed vice president of investor relations and communications at Kymera. Most recently, Cox served as vice president of investor relations at Voyager Therapeutics.
LIDDS has appointed Nina Herne CEO of the company. Herne previously served as project manager at Affibody.
Jack Howarth has been named senior vice president of investor relations at MiMedx Group. Howarth previously served as vice president of corporate affairs at Antares Pharmaceuticals.
Quanterix has named William Geist chief operating officer of the company. Prior to joining Quanterix, Geist was the vice president and general manager for protein and cell analysis and qPCR business units at Thermo Fisher Scientific.
Contract development and manufacturing organization Recro has named David Enloe the company’s new president and CEO. Enloe was most recently president and CEO of Ajinomoto Bio-Pharma Services.
Samsung Biologics has appointed John Rim president and CEO of the company. Rim was most recently the vice president of global product development procurement and research at Roche.
Dallan Murray has been named chief commercial officer of Sarepta Therapeutics. Murray previously served as the company’s vice president of commercial strategy and portfolio management. Sarepta has also appointed Louise Rodino-Klapac, the company’s former senior vice president
of gene therapy, to the role of chief scientific officer.
SpringWorks Therapeutics has promoted Badreddin Edris, the current chief business officer, to chief operating officer, and L. Mary Smith, the company’s senior vice president of clinical research and development, to chief development officer. Prior to joining SpringWorks, Edris was an investment and operating professional at OrbiMed, and Smith served as executive vice president of gene therapy at Bamboo Therapeutics.
Diego Cadavid, former senior vice president and head of clinical development at Fulcrum Therapeutics, has been appointed chief medical officer of X4 Pharmaceuticals.